These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29110022)

  • 1. Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare).
    Schaarschmidt ML; Herr R; Gutknecht M; Wroblewska K; Gerdes S; Sticherling M; Augustin M; Peitsch WK
    Acta Derm Venereol; 2018 Feb; 98(2):200-205. PubMed ID: 29110022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment.
    Gonzalez JM; Johnson FR; McAteer H; Posner J; Mughal F
    Br J Dermatol; 2017 Mar; 176(3):777-785. PubMed ID: 27292093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.
    Kromer C; Schaarschmidt ML; Schmieder A; Herr R; Goerdt S; Peitsch WK
    PLoS One; 2015; 10(6):e0129120. PubMed ID: 26058083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.
    Schaarschmidt ML; Kromer C; Herr R; Schmieder A; Sonntag D; Goerdt S; Peitsch WK
    PLoS One; 2015; 10(12):e0144335. PubMed ID: 26633680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes.
    Schaarschmidt ML; Schmieder A; Umar N; Terris D; Goebeler M; Goerdt S; Peitsch WK
    Arch Dermatol; 2011 Nov; 147(11):1285-94. PubMed ID: 22106115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States.
    Feldman SR; Regnier SA; Chirilov A; Hey F; Gilloteau I; Cella D
    J Am Acad Dermatol; 2019 Jun; 80(6):1650-1657. PubMed ID: 30703461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient preferences for psoriasis treatments: impact of treatment experience.
    Schaarschmidt ML; Umar N; Schmieder A; Terris DD; Goebeler M; Goerdt S; Peitsch WK
    J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):187-98. PubMed ID: 22225546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments.
    Sain N; Willems D; Charokopou M; Hiligsmann M
    Curr Med Res Opin; 2020 Aug; 36(8):1257-1275. PubMed ID: 32468865
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of childhood psoriasis in France. A national survey among general practitioners, pediatricians, and dermatologists.
    Mahé E; Bursztejn AC; Phan A; Corgibet F; Beauchet A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29193624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient preference for biologic treatments of psoriasis in Japan.
    Tada Y; Ishii K; Kimura J; Hanada K; Kawaguchi I
    J Dermatol; 2019 Jun; 46(6):466-477. PubMed ID: 30985030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physicians' criteria in the choice of treatment.
    Makras P; Galanos A; Rizou S; Anastasilakis AD; Lyritis GP
    Hormones (Athens); 2016 Jul; 15(3):413-422. PubMed ID: 27394706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient preferences for topical psoriasis treatments: a discrete choice experiment.
    Hoelker S; Ninosu N; Buettner S; Peitsch WK; Schaarschmidt ML
    J Dermatolog Treat; 2022 Aug; 33(5):2595-2604. PubMed ID: 35373695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.
    Kromer C; Peitsch WK; Herr R; Schmieder A; Sonntag D; Schaarschmidt ML
    J Dtsch Dermatol Ges; 2017 Feb; 15(2):189-200. PubMed ID: 28214326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis.
    DI Lernia V; Neri I; Calzavara Pinton P; DI Nuzzo S; Stingeni L; Guarneri C; Belloni Fortina A; Bonamonte D; Cambiaghi S; Lasagni C; Panzone M; Corazza M; Offidani A; Gisondi P
    G Ital Dermatol Venereol; 2017 Aug; 152(4):327-332. PubMed ID: 26761766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists.
    Ashcroft DM; Seston E; Griffiths CE
    Br J Dermatol; 2006 Dec; 155(6):1236-41. PubMed ID: 17107395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elicitation and use of patients' preferences in the treatment of psoriasis: a systematic review.
    Umar N; Yamamoto S; Loerbroks A; Terris D
    Acta Derm Venereol; 2012 Jul; 92(4):341-6. PubMed ID: 22278662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
    van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes associated with matching patients' treatment preferences to physicians' recommendations: study methodology.
    Umar N; Litaker D; Schaarschmidt ML; Peitsch WK; Schmieder A; Terris DD
    BMC Health Serv Res; 2012 Jan; 12():1. PubMed ID: 22214259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
    Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.